Outlook Therapeutics Sponsored Study Titled 'A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders (NORSE SEVEN)' Posted To ClinicalTrials.gov; Study Not Recruiting